In contrast, in metastatic triple-negative BC (TNBC), PIK3CA mutations are associated with a better outcome with a 10-month increase in median OS, in part due to a higher proportion of PI3K mutations in patients with primary HR+/HER2− BC who become triple-negative upon relapse [24]. Here, PIK3CA is linked to breast cancer.